Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251354 | 1.00 | BRD4 (0.40) | BRD4CREBBPHSD17B2TAS1R3TAS1R1 | |
| SCHEMBL24251567 | 0.94 | P2RX7 (0.38) | BRD4CREBBPHSD17B2TAS1R3TAS1R1 | |
| SCHEMBL24251500 | 0.94 | BRD4 (0.37) | BRD4CREBBPHSD17B2TAS1R3TAS1R1 | |
| SCHEMBL24251419 | 0.92 | BRD4 (0.38) | BRD4CREBBPHSD17B2TAS1R3TAS1R1 | |
| SCHEMBL24251382 | 0.90 | HSD17B2 (0.38) | BRD4CREBBPHSD17B2TAS1R3TAS1R1 | |
| SCHEMBL24251465 | 0.89 | HSD17B2 (0.37) | BRD4CREBBPHSD17B2TRPV1NTRK1 | |
| SCHEMBL24251379 | 0.88 | HSD17B2 (0.39) | BRD4CREBBPHSD17B2TAS1R3TAS1R1 | |
| SCHEMBL23343385 | 0.87 | BRD4 (0.39) | BRD4CREBBPHSD17B2TAS1R3TAS1R1 | |
| SCHEMBL24251434 | 0.87 | HSD17B2 (0.44) | BRD4CREBBPHSD17B2TAS1R3TAS1R1 | |
| SCHEMBL24251374 | 0.86 | TAS1R3 (0.49) | TAS1R3TAS1R1TAS1R2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243197-A1 | Anthelmintic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-07-31 | — | — | US | disclosed |
| US-12269822-B2 | Anthelminthic heterocyclic compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-04-08 | — | — | US | disclosed |
| CN-112996788-B | Anthelmintic heterocyclic compounds | 勃林格殷格翰动物保健美国公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| EP-3820870-A1 | ANTHELMINTHIC HETEROCYCLIC COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | SDHA, PAH, PIGS | BRD4 2177/4885CREBBP 4217/4885HSD17B2 909/4885 |
| US-12269822-B2 | Anthelminthic heterocyclic compounds | SDHA, PAH, PIGS | BRD4 2177/4885CREBBP 4217/4885HSD17B2 909/4885 |
| US-20250243197-A1 | Anthelmintic Heterocyclic Compounds | PAH, PIGS, SDHA | BRD4 1952/4885CREBBP 4253/4885HSD17B2 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.